dual 4-1BB costimulator/anti-Nectin-4 (NovaRock Biotherapeutics)

N/A

Report date: 2025/06/11 10:30:35

Base Information

Drug Namedual 4-1BB costimulator/anti-Nectin-4 (NovaRock Biotherapeutics)
Drug Alias NameNECTIN4-CD137 targeting bispecific antibody (NovaRock Biotherapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsImmunostimulantsT lymphocytes stimulants +[4] 
TargetsNectin-4Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsUrinary Bladder NeoplasmsEsophageal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovarock Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovarock Biotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsEsophageal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A